Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry.
+ 2 more risks
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Orgenesis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ORGS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ORGS underperformed the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: ORGS underperformed the US Market which returned -10.4% over the past year.
Price Volatility Vs. Market
How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StWhat Kind Of Shareholders Own Orgenesis Inc. (NASDAQ:ORGS)?
2 months ago | Simply Wall StBefore You Buy Orgenesis Inc. (NASDAQ:ORGS), Consider Its Volatility
4 months ago | Simply Wall StHow Much Of Orgenesis Inc. (NASDAQ:ORGS) Do Insiders Own?
Is Orgenesis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ORGS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ORGS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORGS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORGS is overvalued based on its PB Ratio (11.1x) compared to the US Biotechs industry average (2.6x).
How is Orgenesis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ORGS's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if ORGS's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ORGS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ORGS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORGS's Return on Equity is forecast to be high in 3 years time
How has Orgenesis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORGS is currently unprofitable.
Growing Profit Margin: ORGS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORGS is unprofitable, and losses have increased over the past 5 years at a rate of -40.7% per year.
Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: ORGS has a negative Return on Equity (-70.32%), as it is currently unprofitable.
How is Orgenesis's financial position?
Financial Position Analysis
Short Term Liabilities: ORGS's short term assets ($26.0M) do not cover its short term liabilities ($31.6M).
Long Term Liabilities: ORGS's short term assets ($26.0M) exceed its long term liabilities ($23.9M).
Debt to Equity History and Analysis
Debt Level: ORGS's debt to equity ratio (39.3%) is considered satisfactory.
Reducing Debt: ORGS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Inventory Level: ORGS has a high level of physical assets or inventory.
Debt Coverage by Assets: ORGS's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORGS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ORGS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -50.4% each year
What is Orgenesis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ORGS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORGS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vered Caplan (50yo)
Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Vered's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD602.37K).
Compensation vs Earnings: Vered's compensation has increased whilst the company is unprofitable.
|Chairperson of the Board||6.25yrs||US$1.40m||no data|
|CFO, Secretary & Treasurer||5.58yrs||US$236.62k||no data|
|President of Masthercell Global||1.17yrs||US$321.36k||no data|
|Chief Executive Officer of Masthercell Global||1.17yrs||US$491.74k||no data|
|Founder & Chief Scientific Officer||no data||US$268.78k||no data|
Experienced Management: ORGS's management team is considered experienced (3.4 years average tenure).
|Chairperson of the Board||6.25yrs||US$1.40m||no data|
|Independent Director||7.83yrs||US$157.00k||no data|
|Scientific Advisor||6.83yrs||US$9.41k||no data|
|Independent Director||6.67yrs||US$181.12k||no data|
|5yrs||no data||no data|
|Independent Director||7.83yrs||US$157.00k||0.34% $209.5k|
|Scientific Advisor||7.83yrs||US$67.20k||no data|
|Scientific Advisor||7.25yrs||US$8.96k||no data|
|Independent Director||3yrs||US$151.06k||no data|
|Member Scientific Advisory Board||1.83yrs||no data||no data|
Experienced Board: ORGS's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.
Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Orgenesis Inc.
- Ticker: ORGS
- Exchange: NasdaqCM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$60.775m
- Shares outstanding: 18.36m
- Website: https://www.orgenesis.com
Number of Employees
- Orgenesis Inc.
- 20271 Goldenrod Lane
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORGS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Oct 2009|
|45O||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Oct 2009|
Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development services, such as manufacturing and development services, and contract manufacturing services. The PT Business segment focuses on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology. It also has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; and Columbia University. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 01:26|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.